Regulatory Outlook finally claims FDA approval for AMD drug PharmaphorumAfter three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 27, 2026) Pharmaphorum After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US. Ophthalmology Read full story Post navigation Previous: Outlook Therapeutics wins FDA approval for Lytenava in wet AMDNext: Argenx deepens immuno expertise with $2.2B Forte Biosciences buy Related Stories Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval pharminent August 17, 2026 Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026
